Prasugrel plus aspirin continued for 30 months compared with 12 months significantly reduced the composite of death, MI, or stroke (3.7% vs 8.8%; HR 0.407; P<0.001) after paclitaxel-eluting stenting.
RCT (n=2,191)
Does 30 months of prasugrel plus aspirin therapy reduce ischemic events compared to 12 months in patients after TAXUS Liberté paclitaxel-eluting stent placement?
Prolonging prasugrel and aspirin therapy to 30 months after paclitaxel-eluting stent placement significantly reduces ischemic events, primarily driven by reductions in MI and stent thrombosis.
Hazard Ratio: 0.407
Absolute Event Rate: 3.7% vs 8.8%
p-value: p=<0.001
BACKGROUND: The TAXUS Liberté Post Approval Study (TL-PAS) contributed patients treated with TAXUS Liberté paclitaxel-eluting stent and prasugrel to the Dual Antiplatelet Therapy Study (DAPT) that compared 12 and 30 months thienopyridine plus aspirin therapy after drug-eluting stents. METHODS AND RESULTS: Outcomes for 2191 TL-PAS patients enrolled into DAPT were assessed. The DAPT coprimary composite end point (death, myocardial infarction MI, or stroke) was lower with 30 compared with 12 months prasugrel treatment (3.7% versus 8.8%; hazard ratio HR, 0.407; P30 months. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00997503.
Garratt et al. (Mon,) conducted a rct in TAXUS Liberté paclitaxel-eluting stent placement (n=2,191). Prasugrel plus aspirin vs. 12 months of prasugrel plus aspirin was evaluated on Composite of death, myocardial infarction, or stroke (HR 0.407, p=<0.001). Prasugrel plus aspirin continued for 30 months compared with 12 months significantly reduced the composite of death, MI, or stroke (3.7% vs 8.8%; HR 0.407; P<0.001) after paclitaxel-eluting stenting.